查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2020214

抗精神病药物市场规模、份额、成长及全球产业分析：按类型、应用和地区划分，并预测至2026-2034年

Antipsychotic Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 195 Pages | 商品交期: 请询问到货日

价格

抗精神病药物市场的成长要素

全球抗精神病药物市场预计在2025年达到185.1亿美元，2026年成长至197.1亿美元，最终在2034年达到274.8亿美元，预测期内复合年增长率（CAGR）为5.24%。北美地区预计将在2025年占据全球市场的主导地位，市场份额高达52.32%，这主要得益于该地区精神疾病的高发生率、众多主要企业生物製药公司的强大影响力以及对技术先进的抗精神病药物的广泛应用。

市场概览

思觉失调症、躁郁症和忧郁症等精神疾病是抗精神病药物市场的主要驱动因素。精神病是这些疾病的主要症状，会影响患者对现实的感知和讯息处理能力。思觉失调症和双相情感障碍盛行率的上升推动了全球对有效抗精神病药物的需求。此外，新型剂型的引入，特别是长效注射剂（LAI），显着提高了治疗顺从性和疗效。

此外，新冠疫情加速了精神科护理领域远距远端医疗的普及，并提高了药物的使用率，从而对市场产生了积极影响。随着医疗保健系统的改善和治疗可近性的提高，预计2024年至2032年间市场成长将趋于稳定。

市场区隔

疾病特异性：

  • 思觉失调症：由于其在全球范围内的高发病率以及几款创新产品的推出，这是我们成长最快的细分市场。
  • 双极性情感障碍：这是第二大类精神疾病，目前已有药物可以帮助稳定症状。终生盛行率约1%，一年盛行率为0.5%。
  • 单相忧郁症：这是第三大类，Rexulti 等药物可以缓解症状。
  • 失智症：由于美国食品药物管理局 (FDA) 的黑框警告限制了抗精神病药物在老年患者中的使用，因此这部分人群占比很小。

依药物类型：

  • 除了安全性更高之外，第二代抗精神病药物，包括Seroquel缓释片、Zyprexa平、维瑞乐、英维加哈菲拉和雷舒利等药物，预计到 2026 年将主导市场，占据 76.12% 的市场份额。
  • 第三代产品预计将展现出最高的复合年增长率，这得益于新产品的推出和技术的进步。
  • 第一代产品由于神经系统副作用风险较高，生长速度最慢。

按药物分类：

  • Aripiprazole正透过向第三代药物的过渡和关键产品核可来推动成长，其中包括 FDA核准的用于治疗思觉失调症和双相情感障碍 I 型的 2 个月缓释注射剂（2022 年）。
  • 棕榈酸帕利哌酮占据第二大的市场份额，这要归功于 Invega Hafiera（2021 年），这是一种每年註射两次的製剂，也是第一个核准用于治疗成人思觉失调症的药物。
  • 其他药物也因可供选择的种类繁多而助长了市场主导地位。

按分销管道：

  • 由于大多数抗精神病药物需要处方笺和后续观察，医院药房占据了最大的市场份额（到 2026 年将达到 43.54%）。
  • 由于网上药局为患者提供了便利，预计它们将增长最快。
  • 药局和零售药局在续开处方笺和供应口服药物方面仍然发挥着至关重要的作用。

区域趋势

  • 北美：受普及、研发和技术采用的推动，预计到 2025 年市场规模将达到 96.9 亿美元，到 2026 年将达到 103.3 亿美元。
  • 欧洲：2025年为39.1亿美元，2026年为41.3亿美元。政府的大力投入和不断提高的意识正在推动市场成长。
  • 亚太地区：预计到 2025 年将达到 37.3 亿美元，到 2026 年将达到 40.3 亿美元。这是成长最快的地区，主要由中国和印度等新兴经济体推动。
  • 拉丁美洲：2025年为7.4亿美元，2026年为7.7亿美元。人们意识的提高和医疗保健支出的增加是推动这一增长的主要因素。
  • 非洲与中东：2025 年为 4.5 亿美元，2026 年为 4.6 亿美元。虽然市场份额有限，但由于医疗基础设施的改善，市场份额正在增长。

市场趋势和驱动因素

1. 采用长效注射剂（LAI）：长效注射剂可提高病患的用药遵从性，并降低復发风险。例如，帕利哌酮长效注射剂每年只需注射四次。

2. 研究与开发 (R&D) 措施：像 Karuna Therapeutics 这样的公司正在开发创新药物，例如 KarXT，用于治疗与思觉失调症和阿兹海默症相关的精神病症状。

3. 精神疾病盛行率上升：世界卫生组织预测，到 2030 年，精神疾病将对全球经济造成 6 兆美元的损失，而且预计需求还会进一步增加。

抑制因子

体重增加、镇静、消化器官系统问题和迟发性运动障碍等副作用会导致患者用药顺从性下降。此外，诸如针对失智症患者的黑框警告等也会限制药物的市场渗透率。

主要企业

  • 强生全球服务有限公司 - Invega Sustaina、 Risperdal Constellation
  • 大冢製药株式会社 - Abilify Maintainer，Lexalti
  • 礼来公司－多种抗精神病药物
  • Teva Pharmaceutical Industries、H. Lundbeck、Bristol-Myers Squibb、Dr. Reddy's Laboratories、Sumitomo Dai Nippon Pharma、Alkermes

产业趋势

  • 2024 年 1 月：梯瓦製药完成了每月一次的Olanzapine平长效注射剂的 3 期试验。
  • 2023 年 4 月：FDA核准了Teva 和 MedinCel 生产的 UZEDY（RisperidoneLAI）。
  • 2022 年 1 月：FDA核准REXULTI 用于治疗 13-17 岁患有思觉失调症的青少年。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 主要国家/地区精神疾病盛行率
  • 精神疾病的成本与负担分析
  • 抗精神病药物研发最新趋势概述
  • 管道分析，主要企业
  • 分析：第一代抗精神病药物与第三代抗精神病药物
  • 重大产业发展、併购等。
  • 新产品发布
  • 新冠疫情的影响：抗精神病药物市场

第五章：2021-2034年全球抗精神病药物市场分析、洞察与预测

  • 市场分析、洞察与预测：按疾病分类。
    • 思觉失调症
    • 躁郁症
    • 单相忧郁症
    • 失智症
    • 其他的
  • 市场分析、洞察与预测：按药物分类
    • Risperidone
    • Quetiapine
    • Olanzapine
    • Aripiprazole
    • Brexpiprazole
    • 棕榈酸帕利哌酮
    • 其他的
  • 市场分析、洞察与预测：按治疗类别划分
    • 第一代
    • 第二代
    • 第三代
  • 市场分析、洞察与预测：按分销管道划分
    • 医院药房
    • 药局和零售药房
    • 网路药房
  • 市场分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美抗精神病药物市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲抗精神病药物市场分析、洞察与预测（2021-2034年）

  • 国家
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区抗精神病药物市场分析、洞察与预测（2021-2034年）

  • 国家
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 东南亚
    • 其他亚太国家

第九章：拉丁美洲抗精神病药物市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲抗精神病药物市场分析、洞察与预测（2021-2034年）

  • 国家
    • GCC
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2026 年）
  • 公司简介
    • Otsuka Pharmaceutical Co., Ltd.
    • Janssen Pharmaceuticals, Inc.（Johnson & Johnson）
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • H. Lundbeck A/S
    • ALLERGAN（AbbVie, Inc.）
    • Eli Lilly and Company
    • Alkermes plc
    • Bristol-Myers Squibb Company
    • Sumitomo Dainippon Pharma Co., Ltd.
Product Code: FBI101390

Growth Factors of antipsychotic drugs Market

The global antipsychotic drugs market was valued at USD 18.51 billion in 2025 and is projected to grow to USD 19.71 billion in 2026, ultimately reaching USD 27.48 billion by 2034, exhibiting a CAGR of 5.24% during the forecast period. North America dominated the global market in 2025 with a share of 52.32%, driven by the high prevalence of psychiatric illnesses, strong presence of leading biopharmaceutical companies, and the adoption of technologically advanced antipsychotic medications.

Market Overview

Psychiatric illnesses, including schizophrenia, bipolar disorder, and depression, are the primary drivers of the antipsychotic drugs market. Psychosis, a key symptom of these illnesses, affects patients' perception of reality and information processing. The rising prevalence of schizophrenia and bipolar disorder has fueled the demand for effective antipsychotic medications globally. Moreover, the adoption of newer drug formulations, particularly long-acting injectables (LAIs), has significantly enhanced treatment adherence and outcomes.

COVID-19 also influenced the market positively by accelerating the transition toward telemedicine for psychiatric care, which increased medication adoption. Market growth is expected to stabilize between 2024 and 2032 due to improved healthcare systems and treatment accessibility.

Market Segmentation

By Disease:

  • Schizophrenia: The fastest-growing segment due to its global prevalence and the launch of multiple innovative products.
  • Bipolar Disorder: Second-largest segment, with drugs helping stabilize symptoms. Lifetime prevalence is around 1%, with a one-year prevalence of 0.5%.
  • Unipolar Depression: Third-largest segment, with medications like Rexulti providing symptomatic relief.
  • Dementia: Smaller segment due to the FDA black box warning limiting antipsychotic use in elderly patients.

By Therapeutic Class:

  • Second Generation Antipsychotics dominated with a 76.12% share in 2026, thanks to a superior safety profile and drugs like SEROQUEL XR, ZYPREXA, VRAYLAR, INVEGA HAFYERA, and Rexulti.
  • Third Generation is expected to exhibit the highest CAGR, supported by new product launches and technological advancements.
  • First Generation shows the lowest growth due to higher risk of neurological side effects.

By Drug:

  • Aripiprazole leads in growth due to third-generation adoption and significant product approvals, including the FDA-approved 2-month LAI for schizophrenia and bipolar I disorder (2022).
  • Paliperidone Palmitate holds the second-largest market share, with INVEGA HAFYERA being the first twice-yearly injectable approved for schizophrenia in adults (2021).
  • Other drugs contribute to market dominance due to the variety of available options.

By Distribution Channel:

  • Hospital pharmacies account for the largest market share (43.54% in 2026) as most antipsychotics require prescription and monitoring.
  • Online pharmacies are expected to grow the fastest due to patient convenience.
  • Drug stores & retail pharmacies remain significant for prescription refills and oral medications.

Regional Insights

  • North America: Market size USD 9.69 billion in 2025, projected USD 10.33 billion in 2026, dominating due to prevalence, R&D, and technological adoption.
  • Europe: USD 3.91 billion in 2025, USD 4.13 billion in 2026; strong government spending and awareness boost market growth.
  • Asia Pacific: USD 3.73 billion in 2025, USD 4.03 billion in 2026; fastest-growing region due to emerging countries like China and India.
  • Latin America: USD 0.74 billion in 2025, USD 0.77 billion in 2026; growth driven by increased awareness and healthcare expenditure.
  • Middle East & Africa: USD 0.45 billion in 2025, USD 0.46 billion in 2026; limited share but growing due to improved healthcare systems.

Market Trends and Growth Drivers

1. Adoption of Long-Acting Injectables (LAIs): LAIs improve adherence and reduce relapse risks. For example, Paliperidone LAIs require administration only four times a year.

2. R&D Initiatives: Companies like Karuna Therapeutics are developing innovative drugs like KarXT for schizophrenia and psychosis in Alzheimer's.

3. Rising Prevalence of Mental Disorders: WHO predicts mental disorders will cost the global economy USD 6 trillion by 2030, intensifying demand.

Restraining Factors

Adverse effects, including weight gain, sedation, digestive issues, and tardive dyskinesia, can lead to non-adherence. Black box warnings, such as for dementia patients, also limit market adoption.

Key Players

  • Janssen Global Services LLC - Invega Sustenna, Risperdal Consta
  • Otsuka Pharmaceutical Co., Ltd. - Abilify Maintena, Rexulti
  • Eli Lilly and Company - Various antipsychotics
  • Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Bristol-Myers Squibb, Dr. Reddy's Laboratories, Sumitomo Dainippon Pharma Co., Alkermes plc

Industry Developments

  • January 2024: Teva completes Phase 3 trial for once-monthly olanzapine LAI.
  • April 2023: FDA approves UZEDY (risperidone LAI) by Teva and MedinCell.
  • January 2022: FDA approves REXULTI for adolescents (13-17 years) with schizophrenia.

Conclusion

The global antipsychotic drugs market is poised for steady growth from 2025 to 2034, driven by rising mental health disorders, innovative LAIs, and active R&D pipelines. North America will continue to lead, while Asia Pacific emerges as the fastest-growing market, supported by awareness programs and increasing patient adoption of modern therapies.

Segmentation By Disease

  • Schizophrenia
  • Bipolar Disorder
  • Unipolar Depression
  • Dementia
  • Others

By Drug

  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Brexpiprazole
  • Paliperidone Palmitate
  • Others

By Therapeutic Class

  • First Generation
  • Second Generation
  • Third Generation

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country)
    • U.S. (By Disease)
    • Canada (By Disease)
  • Europe (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
    • Germany (By Disease)
    • U.K. (By Disease)
    • France (By Disease)
    • Italy (By Disease)
    • Spain (By Disease)
    • Scandinavia (By Disease)
    • Rest of Europe (By Disease)
  • Asia Pacific (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
    • China (By Disease)
    • Japan (By Disease)
    • India (By Disease)
    • Australia (By Disease)
    • Southeast Asia (By Disease)
    • Rest of Asia Pacific (By Disease)
  • Latin America (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
    • Brazil (By Disease)
    • Mexico (By Disease)
    • Rest of Latin America (By Disease)
  • Middle East & Africa (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
    • GCC (By Disease)
    • South Africa (By Disease)
    • Rest of Middle East & Africa (By Disease)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Psychiatric Disorders, By Key Countries/Regions
  • 4.2. Analysis of the Cost and Burden of Mental Health Disorders
  • 4.3. Overview of Current Advances in R&D for Antipsychotic Drugs
  • 4.4. Pipeline Analysis, Key Players
  • 4.5. Analysis: First Generation Antipsychotics vs. Third Generation Antipsychotics
  • 4.6. Key Industry Developments, Mergers, Acquisitions, Etc.
  • 4.7. New Product Launches
  • 4.8. Impact of COVID-19 on Antipsychotic Drugs Market

5. Global Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast- By Disease
    • 5.1.1. Schizophrenia
    • 5.1.2. Bipolar Disorder
    • 5.1.3. Unipolar Depression
    • 5.1.4. Dementia
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast- By Drug
    • 5.2.1. Risperidone
    • 5.2.2. Quetiapine
    • 5.2.3. Olanzapine
    • 5.2.4. Aripiprazole
    • 5.2.5. Brexpiprazole
    • 5.2.6. Paliperidone Palmitate
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 5.3.1. First Generation
    • 5.3.2. Second Generation
    • 5.3.3. Third Generation
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast- By Disease
    • 6.1.1. Schizophrenia
    • 6.1.2. Bipolar Disorder
    • 6.1.3. Unipolar Depression
    • 6.1.4. Dementia
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast- By Drug
    • 6.2.1. Risperidone
    • 6.2.2. Quetiapine
    • 6.2.3. Olanzapine
    • 6.2.4. Aripiprazole
    • 6.2.5. Brexpiprazole
    • 6.2.6. Paliperidone Palmitate
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 6.3.1. First Generation
    • 6.3.2. Second Generation
    • 6.3.3. Third Generation
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
      • 6.5.1.1. By Disease
    • 6.5.2. Canada
      • 6.5.2.1. By Disease

7. Europe Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast- By Disease
    • 7.1.1. Schizophrenia
    • 7.1.2. Bipolar Disorder
    • 7.1.3. Unipolar Depression
    • 7.1.4. Dementia
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast- By Drug
    • 7.2.1. Risperidone
    • 7.2.2. Quetiapine
    • 7.2.3. Olanzapine
    • 7.2.4. Aripiprazole
    • 7.2.5. Brexpiprazole
    • 7.2.6. Paliperidone Palmitate
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 7.3.1. First Generation
    • 7.3.2. Second Generation
    • 7.3.3. Third Generation
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
      • 7.5.1.1. By Disease
    • 7.5.2. U.K.
      • 7.5.2.1. By Disease
    • 7.5.3. France
      • 7.5.3.1. By Disease
    • 7.5.4. Italy
      • 7.5.4.1. By Disease
    • 7.5.5. Spain
      • 7.5.5.1. By Disease
    • 7.5.6. Scandinavia
      • 7.5.6.1. By Disease
    • 7.5.7. Rest of Europe
      • 7.5.7.1. By Disease

8. Asia Pacific Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast- By Disease
    • 8.1.1. Schizophrenia
    • 8.1.2. Bipolar Disorder
    • 8.1.3. Unipolar Depression
    • 8.1.4. Dementia
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast- By Drug
    • 8.2.1. Risperidone
    • 8.2.2. Quetiapine
    • 8.2.3. Olanzapine
    • 8.2.4. Aripiprazole
    • 8.2.5. Brexpiprazole
    • 8.2.6. Paliperidone Palmitate
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 8.3.1. First Generation
    • 8.3.2. Second Generation
    • 8.3.3. Third Generation
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
      • 8.5.1.1. By Disease
    • 8.5.2. India
      • 8.5.2.1. By Disease
    • 8.5.3. Japan
      • 8.5.3.1. By Disease
    • 8.5.4. Australia
      • 8.5.4.1. By Disease
    • 8.5.5. Southeast Asia
      • 8.5.5.1. By Disease
    • 8.5.6. Rest of Asia Pacific
      • 8.5.6.1. By Disease

9. Latin America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast- By Disease
    • 9.1.1. Schizophrenia
    • 9.1.2. Bipolar Disorder
    • 9.1.3. Unipolar Depression
    • 9.1.4. Dementia
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast- By Drug
    • 9.2.1. Risperidone
    • 9.2.2. Quetiapine
    • 9.2.3. Olanzapine
    • 9.2.4. Aripiprazole
    • 9.2.5. Brexpiprazole
    • 9.2.6. Paliperidone Palmitate
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 9.3.1. First Generation
    • 9.3.2. Second Generation
    • 9.3.3. Third Generation
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
      • 9.5.1.1. By Disease
    • 9.5.2. Mexico
      • 9.5.2.1. By Disease
    • 9.5.3. Rest of Latin America
      • 9.5.3.1. By Disease

10. Middle East & Africa Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast- By Disease
    • 10.1.1. Schizophrenia
    • 10.1.2. Bipolar Disorder
    • 10.1.3. Unipolar Depression
    • 10.1.4. Dementia
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast- By Drug
    • 10.2.1. Risperidone
    • 10.2.2. Quetiapine
    • 10.2.3. Olanzapine
    • 10.2.4. Aripiprazole
    • 10.2.5. Brexpiprazole
    • 10.2.6. Paliperidone Palmitate
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 10.3.1. First Generation
    • 10.3.2. Second Generation
    • 10.3.3. Third Generation
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
      • 10.5.1.1. By Disease
    • 10.5.2. South Africa
      • 10.5.2.1. By Disease
    • 10.5.3. Rest of Middle East & Africa
      • 10.5.3.1. By Disease

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles
    • 11.2.1. Otsuka Pharmaceutical Co., Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Teva Pharmaceutical Industries Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Dr. Reddy's Laboratories Ltd.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. H. Lundbeck A/S
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. ALLERGAN (AbbVie, Inc.)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Eli Lilly and Company
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Alkermes plc
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bristol-Myers Squibb Company
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Sumitomo Dainippon Pharma Co., Ltd.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 01: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 02: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 03: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 04: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 05: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 06: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 07: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 08: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 09: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 10: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: U.S. Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 12: Canada Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 13: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 14: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 15: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 16: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 17: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 18: Germany Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 19: U.K. Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 20: France Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 21: Italy Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 22: Spain Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 23: Scandinavia Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 24: Rest of Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 25: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 26: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 27: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 28: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 29: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 30: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: China Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 32: India Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 33: Japan Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 34: Australia Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 35: South East Asia Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 36: Rest of Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 37: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 38: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 39: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 40: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 41: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 42: Brazil Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 43: Mexico Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 44: Rest of Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 45: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 46: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 47: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 48: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 49: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 50: South Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 51: GCC Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 52: Rest of Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034

List of Figures

  • Figure 01: Global Antipsychotic Drugs Market Value Share (%), By Disease, 2026 & 2034
  • Figure 02: Global Antipsychotic Drugs Market Value Share (%), By Drug, 2026 & 2034
  • Figure 03: Global Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026 & 2034
  • Figure 04: Global Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026 & 2034
  • Figure 05: Global Antipsychotic Drugs Market Value Share (%), By Region, 2026 & 2034
  • Figure 06: North America Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 07: North America Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 08: North America Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 09: North America Antipsychotic Drugs Market Value Share (%), By Drug, 2026
  • Figure 10: North America Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 11: North America Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 12: North America Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
  • Figure 13: North America Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
  • Figure 14: North America Antipsychotic Drugs Market Value (USD billion), By Country, 2026 & 2034
  • Figure 15: North America Antipsychotic Drugs Market Value Share (%), By Country, 2026
  • Figure 16: Europe Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 17: Europe Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 18: Europe Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 19: Europe Antipsychotic Drugs Market Value Share (%), By Drug, 2026
  • Figure 20: Europe Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 21: Europe Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 22: Europe Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
  • Figure 23: Europe Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026 & 2034
  • Figure 24: Europe Antipsychotic Drugs Market Value (USD billion), By Country/Sub-region, 2026 & 2034
  • Figure 25: Europe Antipsychotic Drugs Market Value Share (%), By Country/Sub-region, 2026
  • Figure 26: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 27: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 28: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 29: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Drug, 2026
  • Figure 30: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 31: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 32: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
  • Figure 33: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
  • Figure 34: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 35: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 36: Latin America Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 37: Latin America Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 38: Latin America Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 39: Latin America Antipsychotic Drugs Market Value Share (%), By Drug, 2026
  • Figure 40: Latin America Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 41: Latin America Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 42: Latin America Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
  • Figure 43: Latin America Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
  • Figure 44: Latin America Antipsychotic Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 45: Latin America Antipsychotic Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 46: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 47: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 48: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 49: Middle East & Africa Antipsychotic Drugs Market Value Share (%),
  • Figure 50: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 51: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 52: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Distribution Channel 2026 & 2034
  • Figure 53: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
  • Figure 54: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 55: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 56: Global Antipsychotic Drugs Market Share Analysis, By Company, 2026